相关参考文献
注意:仅列出部分参考文献,下载原文获取全部文献信息。It takes two to tango: breakthrough advanced hepatocellular carcinoma treatment that combines anti-angiogenesis and immune checkpoint blockade
Tsung-Hao Liu et al.
JOURNAL OF THE FORMOSAN MEDICAL ASSOCIATION (2021)
Atezolizumab plus Bevacizumab in Unresectable Hepatocellular Carcinoma
Richard S. Finn et al.
NEW ENGLAND JOURNAL OF MEDICINE (2020)
Phase Ib Study of Lenvatinib Plus Pembrolizumab in Patients With Unresectable Hepatocellular Carcinoma
Richard S. Finn et al.
JOURNAL OF CLINICAL ONCOLOGY (2020)
Atezolizumab with or without bevacizumab in unresectable hepatocellular carcinoma (GO30140): an open-label, multicentre, phase 1b study
Michael S Lee et al.
LANCET ONCOLOGY (2020)
Klotho-beta and fibroblast growth factor 19 expression correlates with early recurrence of resectable hepatocellular carcinoma
Zhong-Zhe Lin et al.
LIVER INTERNATIONAL (2019)
A phase 1 study of filanesib, carfilzomib, and dexamethasone in patients with relapsed and/or refractory multiple myeloma
Hans C. Lee et al.
BLOOD CANCER JOURNAL (2019)
Growth arrest and apoptosis induced by kinesin Eg5 inhibitor K858 and by its 1,3,4-thiadiazoline analogue in tumor cells
Sabrina Giantulli et al.
ANTI-CANCER DRUGS (2018)
High Eg5 expression predicts poor prognosis in breast cancer
Qin Jin et al.
ONCOTARGET (2017)
Eg5 inhibitor YL001 induces mitotic arrest and inhibits tumor proliferation
Yufei Wang et al.
ONCOTARGET (2017)
A Phase 1 and 2 Study of Filanesib Alone and in Combination With Low-Dose Dexamethasone in Relapsed/Refractory Multiple Myeloma
Jatin J. Shah et al.
CANCER (2017)
Eg5 Overexpression Is Predictive of Poor Prognosis in Hepatocellular Carcinoma Patients
Can Liu et al.
DISEASE MARKERS (2017)
Modified CLIP with objective liver reserve assessment retains prognosis prediction for patients with advanced hepatocellular carcinoma
Yu-Yun Shao et al.
JOURNAL OF GASTROENTEROLOGY AND HEPATOLOGY (2016)
The prognostic role of Eg5 expression in laryngeal squamous cell carcinoma
Meiping Lu et al.
PATHOLOGY (2016)
First-in-human phase 1 study of filanesib (ARRY-520), a kinesin spindle protein inhibitor, in patients with advanced solid tumors
Patricia M. LoRusso et al.
INVESTIGATIONAL NEW DRUGS (2015)
A Novel Eg5 Inhibitor (LY2523355) Causes Mitotic Arrest and Apoptosis in Cancer Cells and Shows Potent Antitumor Activity in Xenograft Tumor Models
Xiang S. Ye et al.
MOLECULAR CANCER THERAPEUTICS (2015)
Prognosis of patients with advanced hepatocellular carcinoma who failed first-line systemic therapy
Yu-Yun Shao et al.
JOURNAL OF HEPATOLOGY (2014)
Synthesis and Evaluation of Biphenyl Compounds as Kinesin Spindle Protein Inhibitors
Jason P. Holland et al.
CHEMISTRY & BIODIVERSITY (2013)
Mitosis as an anti-cancer drug target
Anna-Leena Salmela et al.
CHROMOSOMA (2013)
Phase II study to assess the efficacy, safety and tolerability of the mitotic spindle kinesin inhibitor AZD4877 in patients with recurrent advanced urothelial cancer
Robert Jones et al.
INVESTIGATIONAL NEW DRUGS (2013)
Phase I/II multicenter study to assess the safety, tolerability, pharmacokinetics and pharmacodynamics of AZD4877 in patients with refractory acute myeloid leukemia
H. M. Kantarjian et al.
INVESTIGATIONAL NEW DRUGS (2012)
Mitosis as an anti-cancer target
A. Janssen et al.
ONCOGENE (2011)
Significance of Aurora B overexpression in hepatocellular carcinoma. Aurora B Overexpression in HCC
Zhong-Zhe Lin et al.
BMC CANCER (2010)
Kinesin motor proteins as targets for cancer therapy
Dennis Huszar et al.
CANCER AND METASTASIS REVIEWS (2009)
K858, a Novel Inhibitor of Mitotic Kinesin Eg5 and Antitumor Agent, Induces Cell Death in Cancer Cells
Ryuichiro Nakai et al.
CANCER RESEARCH (2009)
The Aurora kinase inhibitor VE-465 has anticancer effects in pre-clinical studies of human hepatocellular carcinoma
Zhong-Zhe Lin et al.
JOURNAL OF HEPATOLOGY (2009)
Targeting the Kinesin Spindle Protein: Basic Principles and Clinical Implications
Vasiliki Sarli et al.
CLINICAL CANCER RESEARCH (2008)
Overexpression of Eg5 causes genomic instability and tumor formation in mice
Andrew Castillo et al.
CANCER RESEARCH (2007)
Development of new cancer therapeutic agents targeting mitosis
Mark R. Miglarese et al.
EXPERT OPINION ON INVESTIGATIONAL DRUGS (2006)
Overexpression and amplification of Aurora-A in hepatocellular carcinoma
YM Jeng et al.
CLINICAL CANCER RESEARCH (2004)